Transaction Description:
PHARMACOLOGICALLY OPTIMIZED TLR5 AGONIST AS A NOVEL THERAPY AGAINST IDIOPATHIC PULMONARY FIBROSIS EXTEND THE PERIOD OF PERFORMANCE 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA), US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USAMRDC) TRANSFERRED TO THE DEFENSE HEALTH AGENCY (DHA) FROM THE U.S. ARMY EFFECTIVE 01 OCTOBER 2022. THIS MODIFICATION REFLECTS CHANGES CONSISTENT WITH THE TRANSFER TO DHA. 2. DIVISION II HAS BEEN UPDATED TO SUPERSEDE DIVISION III, SUBDIVISION B, PARAGRAPH 18.